ClinicaliQ Trial Snapshot
- Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma — Recruiting • Oncology • NCT04234022.
- What is being tested: Zn-DDC (Imuthiol), an intravenous agent designed to target cancer stem cells in multiple myeloma by disrupting the hypoxia-NFkappaB-CSC pathway, which is a mechanism previously shown to be effective against cancer stem cells in early studies.
- Patient eligibility overview: The trial recruits patients with multiple myeloma, though specific eligibility criteria regarding disease stage, prior treatment lines, and performance status would be detailed in the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordable drug to study on it's own as well as in combination with other drugs in myeloma…
Eligibility Snapshot
- : * Patients diagnosed with haematological malignancy - either myeloma or acute leukaemia * Patients must be 18 years or over * Patients must be willing and able to give informed consent
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.